Bakkt Schedules Conference Call to Discuss Second Quarter 2025 Results
Investors and analysts interested in participating in the earnings conference call are invited to join at https://events.q4inc.com/attendee/400104648 or dial in at (833) 470-1428 or (404) 975-4839, and reference participant access code 446108 approximately ten minutes prior to the start of the call.
The conference call will be webcast live and archived on the investor relations section of Bakkt's corporate website under the 'Events & Presentations' section, along with any related earnings materials.
About Bakkt
Founded in 2018, Bakkt builds solutions that enable our clients to grow with the crypto economy. Through institutional-grade trading and onramp capabilities, our clients leverage technology that's built for sustainable, long-term involvement in crypto.
Bakkt is headquartered in Alpharetta, GA. For more information, visit: https://www.bakkt.com/ | X - @Bakkt | LinkedIn.
Bakkt-C
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
12 minutes ago
- Business Wire
AGL Investors Have Opportunity to Join agilon health, inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of agilon health, inc. ('Agilon' or 'the Company') (NYSE: AGL) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Agilon announced on August 4, 2025, that President and CEO Steven Sell was stepping down immediately. The Company also withdrew its full-year 2025 financial guidance. Based on this news, shares of Agilon fell by more than 27.2% in after hours trading on the same day. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Business Upturn
44 minutes ago
- Business Upturn
CYCLACEL PHARMACEUTICALS HIGHLIGHTS PRECLINICAL DATA SHOWING THAT CANCER OF THE BILIARY TRACT IS SENSITIVE TO PLOGOSERTIB
– Biliary tract cancer (BTC) or cholangiocarcinoma is an aggressive tumor with poor prognosis – KUALA LUMPUR, Malaysia, Aug. 04, 2025 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; 'Cyclacel' or the 'Company'), a biopharmaceutical company developing innovative cancer medicines, highlighted a preclinical study from independent investigators titled, ' Evaluation of antitumor effects of plogosertib, PLK1 inhibitor in biliary tract cancer with BUBR1 as a potential biomarker ' in the journal, Cancer Research, previously reported in a poster at the American Association of Cancer Research 2025 annual meeting.1 The investigators found that several BTC cancer cell lines were sensitive to plogosertib both as monotherapy and in combinations. Consistently with its antimitotic mechanism of action, plogosertib promoted mitotic checkpoint complex (MCC) formation in prometaphase, which induced mitotic arrest resulting in apoptosis of BTC cells. The authors have also found that BUBR1, a critical mitotic checkpoint protein, may be useful as a biomarker to assess plogosertib's effectiveness. BTC cells with high BUBR1 expression were found to be more sensitive to plogosertib compared to those with low expression. The study concluded that BTC cells with high BUBR1 expression are sensitive to the PLK1 inhibitor plogosertib that demonstrate synergistic effects when combined with an ATR inhibitor, which suggest that targeting PLK1 could be an effective strategy for BTC treatment, especially with BUBR1 expression as a potential biomarker to inform optimal combination therapies. About Biliary Tract Cancer (BTC) BTC, also called cholangiocarcinoma, is a rare but aggressive cancer occurring in the biliary tract, a network of small tubes, or ducts, connecting the liver, gallbladder and small intestine. According to estimates from the National Cancer Institute's SEER database annual US incidence of BTC is 4.4 per 100,000. Prognosis for BTC patients is poor with 5-year overall survival of approximately 10–40% even after surgical tumor resection. BTC treatment strategies include chemotherapy, surgery, radiation and targeted medicines depending on location and stage. As these approaches are not curative, there is an urgent, unmet medical need to treat patients with relapsed, refractory and/or unresectable BTC. About Polo-like Kinase and Plogosertib Polo-like kinase 1 (PLK1) is a serine/threonine kinase that plays a central role in cell division or mitosis. PLK1 is an important regulator of the DNA damage cell cycle checkpoint, mitotic entry and exit, spindle formation and cytokinesis, or cell separation into daughter cells. In general, cancer cells, and in particular KRAS mutated and p53(-) cells, are very sensitive to PLK1 depletion. In contrast normal cells with intact cell cycle checkpoints are less sensitive. Pharmacological inhibition of PLK1 in cancer cells blocks proliferation by prolonged mitotic arrest and induces onset of apoptotic death of such cells. Plogosertib (formerly CYC140) is a novel, small molecule, selective and potent PLK1 inhibitor. It has demonstrated impressive efficacy in human tumor xenografts at nontoxic doses. Cyclacel's translational biology program supports the development of plogosertib in solid tumors and leukemias. Preclinical data from independent groups have shown that certain ARID1A- and/or SMARCA-mutated cancers, and cancers associated with DNAJ-PKAc fusions, may benefit from treatment with plogosertib. Additionally, recent data suggest that PLK1 inhibition may be effective in KRAS-mutated metastatic colorectal cancer. PLK1 overexpression correlates with poor patient prognosis in several tumors, including biliary tract, esophageal, fibrolamellar liver, gastric, leukemia, lung, ovarian, and squamous cell cancers, as well as MYC-amplified cancers. Initial dose escalation data from a Phase 1 clinical study of oral plogosertib suggest that the compound is well tolerated with no dose limiting toxicity observed in five dosing schedules. Clinical benefit was observed in patients with adenoid cystic, biliary tract, ovarian, and squamous cell sinus cancers. About Cyclacel Pharmaceuticals, Inc. Cyclacel is a clinical-stage, biopharmaceutical company developing innovative cancer medicines based on cell cycle and mitosis biology. The anti-mitotic program is evaluating plogosertib, a PLK1 inhibitor, in patients with both solid tumors and hematological malignancies. Cyclacel's strategy is to build a diversified biopharmaceutical business based on a pipeline of novel drug candidates addressing oncology and hematology indications. For additional information, please visit Forward-looking Statements This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended and the Safe Harbor provisions of the US Private Securities Litigation Reform Act of 1995, and encompasses all statements, other than statements of historical fact contained in this press release. These forward-looking statements can be identified by terminology such as 'may,' 'could,' 'will,' 'expects,' 'anticipates,' 'aims,' 'future,' 'intends,' 'plans,' 'believes,' 'estimates,' 'targets,' 'likely to', 'understands' and similar statements. These forward-looking statements are based on management's current expectations. However, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. These statements are neither promises nor guarantees but involve known and unknown risks, uncertainties and other important factors and circumstances that may cause Cyclacel's actual results, performance or achievements to be materially different from its expectations expressed or implied by the forward-looking statements, including conditions in the U.S. capital markets, negative global economic conditions, potential negative developments resulting from epidemics or natural disasters, other negative developments in Cyclacel's business or unfavorable legislative or regulatory developments. We caution you therefore against relying on these forward-looking statements, and we qualify all of our forward-looking statements by these cautionary statements. For a discussion of additional factors that may affect the outcome of such forward-looking statements, see our 2024 annual report on Form 10-K, and in particular the 'Risk Factors' section, as well as the other documents filed with or furnished to the SEC by Cyclacel from time to time. Copies of these filings are available online from the SEC at or on the SEC Filings section of our Investor Relations website at These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. These forward-looking statements should not be relied upon as representing Cyclacel's views as of any date subsequent to the date of this press release. All forward-looking statements in this press release are based on information currently available to Cyclacel, and Cyclacel and its authorized representatives assume no obligation to update these forward-looking statements in light of new information or future events. Accordingly, undue reliance should not be placed upon the forward-looking statements. Contact Cyclacel Pharmaceuticals, Inc. Email: [email protected] © Copyright 2025 Cyclacel Pharmaceuticals, Inc. All Rights Reserved. The Cyclacel logo and Cyclacel® are trademarks of Cyclacel Pharmaceuticals, Inc. SOURCE: Cyclacel Pharmaceuticals, Inc. 1 Yoojin Jeong, Yoojin Jeong, et al, Abstract 5406: Evaluation of antitumor effects of plogosertib, PLK1 inhibitor in biliary tract cancer with BUBR1 as a potential biomarker, Cancer Res (2025) 85 (8 Supplement 1): 5406. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Yahoo
an hour ago
- Yahoo
Big-Box Battle: Should You Stock Up on Costco or BJ's?
Key Points Warehouse clubs like Costco and BJ's are thriving as shoppers seek value in a shaky economy. Costco offers global scale and steady performance, while BJ's is gaining ground with digital growth and expansion. Investors must weigh BJ's growth potential against Costco's proven consistency, or decide to put both in their portfolio's shopping cart. 10 stocks we like better than Costco Wholesale › In today's tightening economy, value (or, at least, the perception of value) reigns supreme among average shoppers. With inflation concerns becoming stronger and whispers of a recession lingering, warehouse clubs are not just thriving, they're stacking profits higher than a pallet of paper towels. Whether you're a family stretching every dollar or an investor looking for upside in retail stocks, Costco (NASDAQ: COST) and BJ's Wholesale Club (NYSE: BJ) are both compelling plays. But they're not created equal. One is a proven juggernaut, while the other is a nimble challenger with momentum. The recession playbook: value and volume Warehouse clubs thrive when consumers start counting pennies. Though it may seem counterintuitive to spend more money upfront, shoppers turn to warehouse clubs in tough times because bulk deals offer a sense of value and stability. When budgets get tight, consumers swap avocado toast for 10-pound bags of rice. Shoppers make the Costco versus BJ's decision based on different priorities. Some gravitate to Costco for its premium private-label goods (like Kirkland), broad international reach, and reputation for quality and consistency. Others prefer BJ's for its lower membership fees, frequent promotions, and the convenience of accepting manufacturer coupons. But when it comes to choosing between them as investments, the decision is more nuanced. Costco, the veteran performer still hitting its marks Costco is the undisputed heavyweight in the warehouse space, with over 900 stores globally — 50% more than it's closest competitor, Sam's Club — and a reputation for low turnover, high renewal rates, and fanatically loyal members. It's not just anecdotal love, either, as the numbers back it up. In May, comparable store sales rose 4.3%. But the real highlight was online sales, which surged 11.6%. That may not sound earth-shattering in an era of two-day shipping, but Costco has traditionally lagged in e-commerce. Seeing double-digit digital growth is a sign that the company isn't resting on its brick-and-mortar laurels. Looking ahead, analysts expect 8% same-store sales growth for Q3, driven largely by stores outside the U.S. The company is also experiencing meaningful growth in the Asia market, with 37 stores in Japan, 20 in Korea, 14 in Taiwan, 7 in China, and more planned for the future. That international tailwind speaks to Costco's global brand power and ongoing expansion opportunities, traits that give the stock its status as a good steady, long-term bet. BJ's, the 'little guy' that's growing fast Then there's BJ's, Costco's smaller rival based mainly on the East Coast. It's gaining ground. While it operates only about a quarter of the clubs Costco does, it's growing faster in both store count and digital capabilities. Membership income is up 8%, a promising sign for a company whose long-term health depends on keeping members engaged and renewing year after year. Perhaps more impressive is BJ's digital progress. Online-influenced sales, like click-and-collect and in-app deals, jumped 35% in Q1. That's not just a flashy stat. It's an indicator that BJ's understands where the modern shopper is headed. While physical traffic still matters, digital channels increasingly influence what, when, and how customers buy. For a company playing catch-up, that kind of digital acceleration could unlock a new tier of growth. But let's not overlook the importance of store expansion, too. While BJ's is opening a similar number of locations a year to Costco, those additions represent a much larger percentage of its total store base, making every new club more impactful to the top line. A faster growth in sales at existing stores, combined with an aggressive store expansion plan creates a powerful growth cocktail, if the company can maintain it. The investor's dilemma: predictability or potential? So, how should investors choose? Both Costco and BJ's benefit from economic headwinds, but they play different roles in an investment portfolio. If you want the blue-chip, time-tested choice, it's Costco. You're paying a premium valuation, but you're getting a strong financial foundation, robust international growth, and one of the stickiest membership models in retail with a 93% renewal rate. . The stock is less likely to wow you with sudden upside, but it's also less likely to surprise you with volatility. BJ's, on the other hand, is cheaper, and not just in the aisles. The stock trades at a discount to Costco by nearly every metric. Can it keep growing memberships while maintaining quality service? Will renewal rates rise as its club footprint expands? Can it hold margins while investing in digital? Those are real risks. But for investors willing to bet on BJs, the upside could be significant. If you're looking for a reliable anchor in turbulent markets, Costco is tough to beat. But if you believe BJ's can continue narrowing the gap, it might be worth giving the underdog a shot. Either way, you won't just be shopping, you'll be stock-piling. Do the experts think Costco Wholesale is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did Costco Wholesale make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,019% vs. just 178% for the S&P — that is beating the market by 841.12%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Philippa Main has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Costco Wholesale. The Motley Fool has a disclosure policy. Big-Box Battle: Should You Stock Up on Costco or BJ's? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
